Publications by authors named "P Deterre"

During inflammatory response, blood leukocytes adhere to the endothelium. This process involves numerous adhesion molecules, including a transmembrane chemokine, CX3CL1, which behaves as a molecular cluster. How this cluster assembles and whether this association has a functional role remain unknown.

View Article and Find Full Text PDF

Sepsis is characterized by a systemic inflammation that can cause an immune dysfunction, for which the underlying mechanisms are unclear. We investigated the impact of cecal ligature and puncture (CLP)-mediated polymicrobial sepsis on monocyte (Mo) mobilization and functions. Our results show that CLP led to two consecutive phases of Mo deployment.

View Article and Find Full Text PDF

The recent decline in global malaria burden has stimulated efforts toward elimination. Understanding the biology of malaria transmission stages may provide opportunities to reduce or prevent onward transmission to mosquitoes. Immature transmission stages, termed stages I to IV gametocytes, sequester in human bone marrow before release into the circulation as mature stage V gametocytes.

View Article and Find Full Text PDF

Malaria caused by Plasmodium falciparum is associated with cytoadherence of infected red blood cells (iRBC) to endothelial cells. Numerous host molecules have been involved in cytoadherence, including the adhesive chemokine CX3CL1. Most of the identified parasite ligands are from the multigenic and hypervariable Plasmodium falciparum Erythrocyte Membrane Protein 1 (PfEMP1) family which makes them poor targets for the development of a broadly protective vaccine.

View Article and Find Full Text PDF
Article Synopsis
  • CCR2 is a crucial target for treating inflammation, and while many antagonists have been developed, none are approved for clinical use yet.
  • Researchers identified a new, short peptide called ECL1i that inhibits CCL2-triggered chemotaxis in human and mouse CCR2, showing selectivity and potency with an IC50 of 2 µM.
  • ECL1i was effective in vivo, reducing recruitment of CCR2-positive cells and slowing disease progression in a mouse model of multiple sclerosis, marking it as the first allosteric inhibitor of CCR2 with functional selectivity.
View Article and Find Full Text PDF